DSM Biologics: Marc Goemans. Offering world-class technologies and manufacturing services to the biopharmaceutical market




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: DSM Biologics: Marc Goemans. Offering world-class technologies and manufacturing services to the biopharmaceutical market
Released on: December 14, 2012. © PharmaTelevision Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
  • Summary
  • Transcript
  • Participants
  • Company
In this episode of PharmaTelevision News Review, filmed at AusBio 2012 in Melbourne, Australia, Fintan Walton talks to Marc Goemans, Senior Director New Business Development Asia – Pacific at DSM Biologics
Marc Goemans's perspective: The field of contract manufacturing in relation to biologics
Fintan Walton:
Hello and welcome to the PharmaTelevision News Review here at AusBiotech, in Melbourne in 2012. On this show I have Marc Goemans, who is Global Vice President of Sales and Marketing at DSM Biologics, welcome.
Marc Goemans:
Thank you.
Fintan Walton:
Mark, you are obviously in the area of biologics for DSM, and of course DSM have a biologics facility here in Australia where we are based, but actually up in Brisbane, So just first of all as somebody who is focused and specialized in the area of biologics how would describe the whole field of contract manufacturing related to biologics at the moment?
Marc Goemans:
I think it's a very exciting field these days, there is a lot of developments going on into the market. Until recently it was mainly developments around new biological entities but in the past few years there is a lot of activity going on in the biosimilars field which brought a different momentum to the market. Second development I would say is the development of single-use technologies. The drive to make the processes more efficient has also made it possible to get into single-use technologies and both of these trends we capture in our units.
Capabilities of DSM Biologics facility in Brisbane
Fintan Walton:
Right, okay, and of course just to stress that you are actually based in Holland obviously?
Marc Goemans:
Correct, yes.
Fintan Walton:
Yes, but then just look at the facility here in Australia, because obviously the move of DSM into biologics here in Australia was quite important for both DSM and obviously for Australia, so describe to us what the DSM Biologics facility in Brisbane is, what does it contain and what are your capabilities?
Marc Goemans:
In the grassroot of Princess Alexandra Hospital in Brisbane next to the Translational Research Institute, we have occupied a building of six floors, those are two paired floors, manufacturing floor, one floor is done for manufacturing and the other one is for the utilities. we have had fit only one pair of floors with two 2000 liter bioreactors, and two 500 liter XD or extreme-density process technologies, all in single-use technologies on those floors, and all in all we will start off with a team of about 50 people growing up to 80 depending on how this develops.
Fintan Walton:
Right, so just to be clear about the capabilities, is it purely mammalian or can it do other organisms as well?
Marc Goemans:
It's a very good question, now it's exclusively to mammalian cell culture, is correct.
Fintan Walton:
Right.
Marc Goemans:
Yes.
Fintan Walton:
And embedded in that technology, embedded in that manufacturing technology, how specific, what does DSM bring to the biologic manufacturing that say other companies don't?
Marc Goemans:
I think a standard offering in the industry is a fed-batch technology, I think that's a little bit of the workhorse in terms of the process time, and what we are bringing are processing technologies, the first one is a bioreactor technology called the extreme-density technology which allows you to make a much more efficient and concentrated manufacturing of your process, and in the downstream process we are also bringing new purification technologies, a robust technology which allows you to tremendously cut in terms of processing time and both of these in the end should bring cost benefits to the customer and drive to under cost for the customer.
Fintan Walton:
Right, now one of the things that we know that's happening in the industry, obviously there is a lot of new innovative molecules making their way through, antibodies are clear leader in that field, but also biosimilars, so just in terms of your antibody expression systems, are you capable of doing, are you, have you got a lead in that area?
Marc Goemans:
The question is we, we are a contract manufacturing so we are not doing our own products. We at this stage are doing, the customers bring their cell lines to us, with the opening of our process development capabilities in Brisbane we are also bringing cell line generation to our portfolio and there we will be able to generate cell lines on the various mammalian cell culture platforms. One is CHO XL99, a cell line generated here in Australia by AIBN, another one is PER.C6 that has been running in our portfolio for a while.
Marc Goemans's views: Biosimilars market and DSM's CMO offerings
Fintan Walton:
Right, and then just in terms of biosimilars, what sort of impact does, has biosimilars had generally in the market but also from a contract manufacturing point of view, if you are a generics company or even an established pharmaceutical, ethical pharmaceutical company, you may be interested in biosimilars, what is, how would you describe that market and again what can DSM do to facilitate the needs of those companies that want to produce biosimilars?
Marc Goemans:
The biosimilar market is really has developed very rapidly but what do we find in our biosimilars customers is that they are very project driven, so they from start to end they know very well what they need basically because the molecule is already there, so that's one drive, so it's very, very quick, quick transition from Phase I to Phase III. Second of all before the drive of lower cost of goods the players in those markets are very receptive to adopt new technologies. The originated products were based on older platforms and there is a need to drive those cost down, they are looking at the generics in the small molecules, they are parallels with things that will be different there, but so there is also a very large acceptance to try out new technologies and those two bring, yes, come very nicely together in our CMO offering, because we can provide that in our single-use and with our new technologies.
DSM's level of support in clinical development
Fintan Walton:
Of course we often look at manufacturing purely from the when the products on the market, but in terms of clinical development what sort of level of support can DSM give at the very early stages when molecules are at the, at still at the very early stage entering clinical trials and so forth?
Marc Goemans:
You mean for biosimilars or for new biologics?
Fintan Walton:
Well both.
Marc Goemans:
Well I mean the clinical support we can provide, I mean we are doing a pre-clinical all the way to Phase III, so we provide support to all clinical phases. I would say that our facility in Netherlands originally was more laid out for preclinical , Phase I, also there we've had recent expansions that we are able to support commercial. The Brisbane unit is also laid out for preclinical but it's larger in scale, so we expect the Brisbane unit to be able to absorb larger amounts of our commercial needs. First of all by the floor that we are laying out, but second of all also by the empty floor that we have and that is on offer either as a multipurpose unit or as a single product units for any customer who would be interested to partner with us.
Challenges and DSM's support in process development
Fintan Walton:
Right, the other component that you've talked about earlier which is the processing end and how important that is, so in terms of the challenges that are, that a company like DSM have to face, in terms of facilitating that for the customer, how much of support can you give to the development of those processes that are required to make that process in the end efficient?
Marc Goemans:
Well the projects that we are running in process development go hand in hand with the customer. The needs are varying, most are very quality driven, and yes we partner up with the customers in getting those technologies to run for our customers. Now we have a very large database of programs that we've run so we will be really able to quickly get the process running on the specs they want, but this is the kind of the support we can provide to our customers, in the end, especially in the biosimilars field, is very much driven to the quantities and the specifications they need.
Fintan Walton:
Okay, yes and then we've talked a lot about mammalian cell systems, what about the microbial side?
Marc Goemans:
Microbial is also a line of business that DSM has in contract manufacturing, but its run from a different business unit in DSM, that business unit is called DSM BioSolutions and that runs its business from in the smaller scale in our research facilities in the Netherlands in Delft, and their commercial skill in the area of Naples, in Italy.
Future capabilities of Brisbane manufacturing facility
Fintan Walton:
Okay, and now in terms of just finally then as we look at the development of the Brisbane manufacturing, as we are here in Australia let's look at that, what are the future capabilities of that particular manufacturing facility?
Marc Goemans:
Well for the future what we see is that we start running, initially start running more clinical trial batches, but the unit is completely laid out for commercial skill. So there is one floor right now fitted out with a variety of bioreactors, the other floor we haven't decided yet, all the utilities are there, but we could design it to our way also very quickly because the shell is there so the time to get it running could be very short and but our view is that in the end will be our unit for commercial supply into the market.
Fintan Walton:
Marc Goemans, thank you very much indeed for coming on the show.
Marc Goemans:
Thank you.
Fintan Walton
Dr Fintan Walton is the Founder and CEO of PharmaVentures . After completing his doctoral research on the genetics of cell proliferation at the University of Michigan(US)and Trinity College (Dublin, Ireland), Dr Walton gained broad commercial experience in biotechnology in management positions at Bass and Celltech plc (1982-1992).
Marc Goemans
VP
At the time of recording this PTV interview Marc Goemans serves as VP Global Marketing & Sales at DSM Biologics. Marc Goemans has 19 Years of experience in various fields of basic chemicals, enzymes, small molecule API's, medical devices and biologics a.o. with Gistbrocades, DSM Anti-Infectives, Medisize and now DSM Biologics. In the last 13 years in commercial roles in various markets, in Europe, USA, Middle East and Asia Pacific. In marketing, sales and business development positions, Leading generic market entry on API's, Contract Manufacturing for Medical Devices and Biologics, Licensing Technologies for API's and Biologicals, Contract Research, Account Management. Now leading the commercial opening per mid 2013 of the new cGMP facility for clinical and commercial mammalian cell culture based manufacturing in Brisbane in collaboration with BPA.
PharmaVentures
PharmaVentures is a corporate finance and transactions advisory firm that has served hundreds of clients worldwide in relation to their strategic deal making in the pharmaceutical, life science and healthcare sectors. Our key offerings include: Transactions / deal negotiations; Product / technology valuations; Deal term advice; Due diligence & expert reports; Strategy formulation; Alliance management; and Expert opinion for litigation/arbitration cases. PharmaVentures provides the global expertise to ensure our clients generate the highest possible return on investment from all their deal making activities. We have experience of all therapeutic areas and can offer advice on both product and technology commercialisation.
DSM Biologics
DSM Biologics a business unit of DSM Pharmaceutical Products, is a global provider of manufacturing technology and services to the biopharmaceutical industry. In addition to the offering of world-class biopharmaceutical manufacturing services, DSM Biologics provides and develops technologies relevant for optimized mammalian cell culture processes. Examples are the proprietary XD Technology for use with mammalian cell lines. The "XD process" leads to very high cell densities within the bioreactor, which result in maximum productivity using readily available equipment. DSM's manufacturing services provides companies with a turn-key biologic manufacturing solution reducing cost, risk and time to market.